Table 1.
Study population demographics by chemotherapy receipt and RS testing
| Received chemotherapy | Did not receive chemotherapy | P value* | |||
|---|---|---|---|---|---|
| Group A with RS (n = 17,807) | Group B no RS (13,612) | Group A with RS (56,971) | Group B no RS (41,375) | ||
| Age, years | <0.0001 | ||||
| <40 | 1156 (6) | 1274 (9) | 1262 (2) | 515 (1) | |
| 40–49 | 4594 (26) | 3900 (29) | 11,140 (20) | 4928 (12) | |
| 50–59 | 6339 (36) | 4506 (33) | 19,320 (34) | 11,694 (28) | |
| 60–70 | 5718 (32) | 3932 (29) | 25,249 (44) | 24,238 (59) | |
| Race | <0.0001 | ||||
| White | 15,151 (85) | 11,219 (82) | 50,249 (88) | 35,979 (87) | |
| Black | 1629 (9) | 1565 (12) | 3957 (7) | 3360 (8) | |
| Other/unknown | 1027 (6) | 828 (6) | 2765 (5) | 2036 (5) | |
| Ethnicity | <0.0001 | ||||
| Mexican/Chicano/other | 95 (1) | 164 (1) | 261 (1) | 327 (1) | |
| Hispanic | 682 (4) | 784 (6) | 1957 (3) | 1683 (4) | |
| Non-Hispanic | 16,284 (91) | 12,188 (90) | 52,329 (92) | 37,889 (92) | |
| Unknown/missing | 746 (4) | 476 (3) | 2424 (4) | 1476 (4) | |
| Insurance status | <0.0001 | ||||
| Private | 13,224 (74) | 9615 (71) | 39,069 (69) | 23,864 (58) | |
| Medicare | 2712 (15) | 2022 (15) | 12,693 (22) | 13,443 (32) | |
| Medicaid | 1163 (7) | 1287 (9) | 3064 (5) | 2356 (6) | |
| Other government | 195 (1) | 155 (1) | 626 (1) | 439 (1) | |
| Not insured/status unknown | 513 (3) | 533 (4) | 1519 (3) | 1273 (3) | |
| Comorbidities (CDCC score) | <0.0001 | ||||
| 0 | 15,508 (87) | 11,842 (87) | 49,166 (86) | 34,761 (84) | |
| 1 | 2039 (11) | 1506 (11) | 6667 (12) | 5368 (13) | |
| 2 | 260 (2) | 264 (2) | 1138 (2) | 1246 (3) | |
| Year of diagnosis | <0.0001 | ||||
| 2010 | 3843(22) | 3779 (27) | 49,166 (86) | 10,083 (25) | |
| 2011 | 4711 (27) | 3653 (27) | 6667 (12) | 10,264 (25) | |
| 2012 | 4505 (25) | 3232 (24) | 1138 (2)) | 10,543 (25) | |
| 2013 | 4748 (26) | 2948 (22) | 10,485 (25) | ||
| Income level (median) | <0.0001 | ||||
| <$38,000 or not available | 2129 (12) | 1938 (15) | 6742 (12) | 5721 (14) | |
| $38,000–$47,999 | 3456 (19) | 2806 (20) | 11,066 (19) | 8545 (20) | |
| $48,000–$62,999 | 4641 (26) | 3679 (27) | 15,268 (27) | 11,045 (27) | |
| ≥$63,000 | 7581 (43) | 5189 (38) | 23,895 (42) | 16,064 (39) | |
| Education (% without post high school) | <0.0001 | ||||
| ≥21 | 2037 (11) | 2082 (15) | 6059 (10) | 5636 (13) | |
| 13–20 | 3864 (22) | 3135 (23) | 11,894 (21) | 9444 (23) | |
| 7–12.9 | 5897 (33) | 4467 (33) | 19,509 (34) | 13,707 (33) | |
| <7 or not available | 6009 (34) | 3928 (29) | 19,509 (34) | 12,588 (31) | |
| Geographic location | <0.0001 | ||||
| Metropolitan | 15,111 (85) | 11,428 (84) | 48,162 (85) | 34,547 (83) | |
| Urban | 2146 (12) | 1743 (13) | 7059 (12) | 5379 (13) | |
| Rural | 128 (1) | 100 (1) | 423 (1) | 297 (1) | |
| Unknown | 422(2) | 341 (2) | 1327 (3) | 1152 (3) | |
| Facility type | <0.0001 | ||||
| Academic/research | 4050 (30) | 18,987(33) | 12,096 (29) | ||
| Non-academic | 6405 (36) 11,402 (64) |
9562 (70) | 37,984 (67) | 29,279 (71) | |
ǂAll measurements reported as frequency and percent
* All p values are based on tests of association between the demographic characteristic and a 4-level variable of chemotherapy receipt (yes/no) and RS assay (yes/no)